GNMK News and Press, GenMark Diagnostics Inc. From 02/25/21

Gainers: [[GRPN]] +12.8%. [[IHRT]] +10.2%. [[ACIW]] +10.1%. [[NTRA]] +8.5%. [[ETSY]] +4%.Losers: [[TCDA]] -23.1%. [[MRIN]] -12.9%. [[TPIC]] -10%. [[TUSK]] -9.6%. [[GNMK]] -9.6%. For further details see: ETSY, GRPN, TPIC and GNMK among after-hours movers

GenMark Diagnostics (GNMK): Q4 GAAP EPS of -$0.05 misses by $0.04.Revenue of $50.08M (+84.1% Y/Y) beats by $1.03M.ePlex® revenue of $45.4M, an increase of 138% Y/Y.Gross margin of 39%, compared to 34% Y/Y.Average annuity per analyzer of $220,000, compared to $148,000 Y/Y.2021 Guidan...

CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 20...

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants c...

Stock market indices stand to finish mixed after a holiday-shortened week where Congressional hearings around GameStop (GME) dominated headlines. The Nasdaq (COMP) may eke out a small gain for the week, while the S&P 500 (SP500) is down about 0.8% at the time of this writing. Dow Industri...

Quidel Corporation ([[QDEL]] -10.9%) has failed to meet the consensus revenue estimates in Q4 2020 despite the surging pandemic driving a ~80.6% YoY sequential growth in revenue from COVID-19 products.Today, the stock is leading a broader selloff among COVID-19 test makers after Evercore ISI ...

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in th...

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highligh...

Gainers: [[EPSN]] +44.1%. [[OCUL]] +18.7%. [[GTHX]] +12.1%. [[YI]] +5.9%. [[CPIX]] +3.9%.Losers: [[EGLE]] -7.0%. [[GRIN]] -6.7%. [[EQ]] -6.3%. [[DSP]] -4.5%. [[GNMK]] -3.9%. For further details see: EPSN, OCUL, GNMK and EQ among after-hours movers

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review th...